Related references
Note: Only part of the references are listed.A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2010)
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma
Jongkonnee Thanasai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed
Elena Di Gennaro et al.
CANCER BIOLOGY & THERAPY (2009)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2009)
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Miriam Koopman et al.
EUROPEAN JOURNAL OF CANCER (2009)
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
William Fazzone et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
Francesca Bruzzese et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
Sharmila Shankar et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity
Vincenzo Guarcello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Targeting platelet-derived endothelial cell growth factor thymidine phosphorylase for cancer therapy
Sandra Liekens et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells
Antonio Avallone et al.
ANTI-CANCER DRUGS (2007)
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Anthony Tumber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Histone deacetylase inhibitors: A new wave of molecular targeted anticancer agents
Alfredo Budillon et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Jane L. Yen et al.
EUROPEAN JOURNAL OF CANCER (2007)
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Ju-Hee Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Review of capecitabine as oral treatment of gastric, gastroesophageal, and Esophageal cancers
Jaffer Ajani
CANCER (2006)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo
F Bruzzese et al.
CLINICAL CANCER RESEARCH (2006)
Update on capecitabine in colorectal cancer
Hans-Joachim Schmoll et al.
ONCOLOGIST (2006)
The role of capecitabine in first-line treatment for patients with metastatic breast cancer
Karen Gelmon et al.
ONCOLOGIST (2006)
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects
C Blanquicett et al.
CLINICAL CANCER RESEARCH (2005)
Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase
A Budillon et al.
CURRENT DRUG TARGETS (2005)
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment
M Toi et al.
LANCET ONCOLOGY (2005)
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer
T Kindwall-Keller et al.
CLINICAL CANCER RESEARCH (2005)
Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials
SH Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
RW Johnstone et al.
CANCER CELL (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Role of platelet-derived enclothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity
M de Bruin et al.
BRITISH JOURNAL OF CANCER (2003)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
